Immune checkpoint blockade in infectious diseases

[1]  Y. Li,et al.  A new checkpoint receptor targets for cancer immunotherapy , 2020, The Journal of Immunology.

[2]  S. Lewin,et al.  OA3-3 Anti-PD-1 disrupts HIV latency in non-proliferating but not in proliferating T cells , 2017 .

[3]  F. Hecht,et al.  Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8+ T Cell Exhaustion Marker Expression. , 2017, AIDS research and human retroviruses.

[4]  M. Kudo,et al.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.

[5]  R. Koup,et al.  Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy , 2017, The Journal of infectious diseases.

[6]  G. Sica,et al.  Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients , 2017, Proceedings of the National Academy of Sciences.

[7]  Jedd D. Wolchok,et al.  T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.

[8]  Jian-hua Li,et al.  Clinical Significance of Dynamics of Programmed Death Ligand-1 Expression on Circulating CD14+ Monocytes and CD19+ B Cells with the Progression of Hepatitis B Virus Infection. , 2017, Viral immunology.

[9]  I. Wistuba,et al.  VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer , 2017, Nature Medicine.

[10]  S. Lewin,et al.  Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus–Infected Individuals Receiving Suppressive Antiretroviral Therapy , 2017, The Journal of infectious diseases.

[11]  W. Dougall,et al.  TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy , 2017, Immunological reviews.

[12]  M. Ferracin,et al.  Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B , 2017, Nature Medicine.

[13]  R. Ahmed,et al.  Dynamics of SIV-specific CXCR5+ CD8 T cells during chronic SIV infection , 2017, Proceedings of the National Academy of Sciences.

[14]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[15]  O. Lund,et al.  Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals , 2017, Scientific Reports.

[16]  R. Bourgon,et al.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial , 2017, The Lancet.

[17]  Todd M. Allen,et al.  The epigenetic landscape of T cell exhaustion , 2016, Science.

[18]  S. Berger,et al.  Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade , 2016, Science.

[19]  R. Noelle,et al.  A New VISTA on combination therapy for negative checkpoint regulator blockade , 2016, Journal of Immunotherapy for Cancer.

[20]  P. Ganz,et al.  Role of T‐Cell Dysfunction, Inflammation, and Coagulation in Microvascular Disease in HIV , 2016, Journal of the American Heart Association.

[21]  X. Piao,et al.  T-Cell Immunoglobulin- and Mucin-Domain-Containing Molecule 3 Signaling Blockade Improves Cell-Mediated Immunity Against Malaria. , 2016, The Journal of infectious diseases.

[22]  S. Abera,et al.  Trends, causes, and risk factors of mortality among children under 5 in Ethiopia, 1990–2013: findings from the Global Burden of Disease Study 2013 , 2016, Population health metrics.

[23]  O. Yang,et al.  Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection , 2016, AIDS.

[24]  Eyal Oren,et al.  Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, The Lancet.

[25]  E. Rakasz,et al.  Simian Immunodeficiency Virus-Producing Cells in Follicles Are Partially Suppressed by CD8+ Cells In Vivo , 2016, Journal of Virology.

[26]  D. Schadendorf,et al.  Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. , 2016, The oncologist.

[27]  N. F. Lima,et al.  Surface expression of inhibitory (CTLA-4) and stimulatory (OX40) receptors by CD4+ regulatory T cell subsets circulating in human malaria. , 2016, Microbes and infection.

[28]  S. Pittaluga,et al.  Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti–programed death-ligand 1 (Avelumab) , 2016, AIDS.

[29]  John J Miles,et al.  Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy , 2016, Clinical Cancer Research.

[30]  Reza Assadi,et al.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 , 2016, The Lancet.

[31]  J. Pawlotsky.  Faculty Opinions recommendation of Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. , 2016 .

[32]  Thomas S. Watkins,et al.  Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4(+) T Cell Immunity. , 2016, Immunity.

[33]  Di Wu,et al.  CXCR5+ follicular cytotoxic T cells control viral infection in B cell follicles , 2016, Nature Immunology.

[34]  L. Chin,et al.  Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. , 2016, Cancer discovery.

[35]  R. Ahmed,et al.  Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion , 2016, Journal of Virology.

[36]  Koichi Araki,et al.  Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent , 2016, Science.

[37]  Richard Jefferys,et al.  International AIDS Society global scientific strategy: towards an HIV cure 2016 , 2016, Nature Medicine.

[38]  R. Phillips,et al.  Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection , 2016, PLoS pathogens.

[39]  S. Lewin,et al.  CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART , 2016, PLoS pathogens.

[40]  G. Pantaleo,et al.  PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals , 2016, Nature Medicine.

[41]  C. Poh,et al.  Mice lacking Programmed cell death-1 show a role for CD8+ T cells in long-term immunity against blood-stage malaria , 2016, Scientific Reports.

[42]  Ana C Anderson,et al.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. , 2016, Immunity.

[43]  E. Wherry,et al.  Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. , 2016, Immunity.

[44]  G. Freeman,et al.  Coinhibitory Pathways in Immunotherapy for Cancer. , 2016, Annual review of immunology.

[45]  M. Lederman,et al.  Inflammation Perturbs the IL-7 Axis, Promoting Senescence and Exhaustion that Broadly Characterize Immune Failure in Treated HIV Infection , 2016, Journal of acquired immune deficiency syndromes.

[46]  F. Zoulim,et al.  Global strategies are required to cure and eliminate HBV infection , 2016, Nature Reviews Gastroenterology and Hepatology.

[47]  T. Ottenhoff,et al.  KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults. , 2016, Tuberculosis.

[48]  A. Madi,et al.  TIM3 Mediates T Cell Exhaustion during Mycobacterium tuberculosis Infection , 2016, PLoS pathogens.

[49]  Wojciech G. Lesniak,et al.  A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors , 2016, Oncotarget.

[50]  J. Soria,et al.  Immune-related adverse events with immune checkpoint blockade: a comprehensive review. , 2016, European journal of cancer.

[51]  G. Cooke,et al.  PD-1 Expression and Cytokine Secretion Profiles of Mycobacterium tuberculosis-Specific CD4+ T-Cell Subsets; Potential Correlates of Containment in HIV-TB Co-Infection , 2016, PloS one.

[52]  M. Ostrowski,et al.  TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection , 2016, PLoS pathogens.

[53]  Gérard Krause,et al.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.

[54]  R. Phillips,et al.  Immunological biomarkers predict HIV-1 viral rebound after treatment interruption , 2015, Nature Communications.

[55]  B. Palmer,et al.  PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing , 2015, PLoS pathogens.

[56]  F. Chisari,et al.  Host-virus interactions in hepatitis B virus infection. , 2015, Current opinion in immunology.

[57]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[58]  A. Korman,et al.  FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. , 2015, Cancer cell.

[59]  A. Ribas,et al.  Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma , 2015, Oncoimmunology.

[60]  G. Freeman,et al.  Nef promotes evasion of human immunodeficiency virus type 1-infected cells from the CTLA-4-mediated inhibition of T-cell activation. , 2015, The Journal of general virology.

[61]  Peter D. Crompton,et al.  PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity. , 2015, Cell host & microbe.

[62]  G. Sotgiu,et al.  Tuberculosis treatment and drug regimens. , 2015, Cold Spring Harbor perspectives in medicine.

[63]  C. Meyer,et al.  Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients , 2015, Proceedings of the National Academy of Sciences.

[64]  C. Qiu,et al.  The Upregulation of LAG-3 on T Cells Defines a Subpopulation with Functional Exhaustion and Correlates with Disease Progression in HIV-Infected Subjects , 2015, The Journal of Immunology.

[65]  S. Lewin,et al.  Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. , 2015, AIDS.

[66]  R. Thimme,et al.  Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. , 2014, Journal of hepatology.

[67]  H. Pircher,et al.  Inhibitory Phenotype of HBV-Specific CD4+ T-Cells Is Characterized by High PD-1 Expression but Absent Coregulation of Multiple Inhibitory Molecules , 2014, PloS one.

[68]  Jeffrey N. Martin,et al.  Programmed death-1 expression on CD4+ and CD8+ T cells in treated and untreated HIV disease , 2014, AIDS.

[69]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  Jia Liu,et al.  Enhancing Virus-Specific Immunity In Vivo by Combining Therapeutic Vaccination and PD-L1 Blockade in Chronic Hepadnaviral Infection , 2014, PLoS pathogens.

[71]  R. Ahmed,et al.  PD-1 dependent exhaustion of CD8+ T cells drives chronic malaria. , 2013, Cell reports.

[72]  P. Doherty,et al.  Highly Pathological Influenza A Virus Infection Is Associated with Augmented Expression of PD-1 by Functionally Compromised Virus-Specific CD8+ T Cells , 2013, Journal of Virology.

[73]  Douglas E. Jones,et al.  Programmed Death 1–Mediated T Cell Exhaustion during Visceral Leishmaniasis Impairs Phagocyte Function , 2013, The Journal of Immunology.

[74]  D. Glass,et al.  Modulation of Treg cells/T effector function by GITR signaling is context–dependent , 2013, European journal of immunology.

[75]  C. Pechmann,et al.  Policy and Research Related to Consumer Rebates: A Comprehensive Review , 2013 .

[76]  Todd M. Allen,et al.  Cutting Edge: Prolonged Exposure to HIV Reinforces a Poised Epigenetic Program for PD-1 Expression in Virus-Specific CD8 T Cells , 2013, The Journal of Immunology.

[77]  Jeffrey N. Martin,et al.  Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. , 2013, The Journal of infectious diseases.

[78]  Zhiwei Chen,et al.  PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice. , 2013, The Journal of clinical investigation.

[79]  S. Beverley,et al.  Parasite-Derived Arginase Influences Secondary Anti-Leishmania Immunity by Regulating Programmed Cell Death-1–Mediated CD4+ T Cell Exhaustion , 2013, The Journal of Immunology.

[80]  Kevin Marsh,et al.  Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. , 2013, The New England journal of medicine.

[81]  Han-Hsuan Fu,et al.  A Potential New Pathway for PD-L1 Costimulation of the CD8-T Cell Response to Listeria monocytogenes Infection , 2013, PloS one.

[82]  Peter D. Crompton,et al.  Chronic Exposure to Plasmodium falciparum Is Associated with Phenotypic Evidence of B and T Cell Exhaustion , 2013, The Journal of Immunology.

[83]  G. Freeman,et al.  Down-Regulation of CTLA-4 by HIV-1 Nef Protein , 2013, PloS one.

[84]  F. Mackay,et al.  Malaria infection alters the expression of B‐cell activating factor resulting in diminished memory antibody responses and survival , 2012, European journal of immunology.

[85]  Qin Cheng,et al.  Artemisinin resistance in Plasmodium falciparum: A process linked to dormancy? , 2012, International journal for parasitology. Drugs and drug resistance.

[86]  Jeffrey N. Martin,et al.  A Randomized Controlled Trial Assessing the Effects of Raltegravir Intensification on Endothelial Function in Treated HIV Infection , 2012, Journal of acquired immune deficiency syndromes.

[87]  W. Rosenberg,et al.  Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection , 2012, PloS one.

[88]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[89]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[90]  G. Freeman,et al.  PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. , 2012, The Journal of clinical investigation.

[91]  D. Hafler,et al.  The TIGIT/CD226 Axis Regulates Human T Cell Function , 2012, The Journal of Immunology.

[92]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[93]  Peter Vogel,et al.  Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape , 2022 .

[94]  Ornella Pagliano,et al.  CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. , 2012, Cancer research.

[95]  L. Rénia,et al.  The CTLA-4 and PD-1/PD-L1 Inhibitory Pathways Independently Regulate Host Resistance to Plasmodium-induced Acute Immune Pathology , 2012, PLoS pathogens.

[96]  P. Klenerman.  Faculty Opinions recommendation of Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. , 2012 .

[97]  V. Kuchroo,et al.  T cell immunoglobulin and mucin protein-3 (Tim-3)/Galectin-9 interaction regulates influenza A virus-specific humoral and CD8 T-cell responses , 2011, Proceedings of the National Academy of Sciences.

[98]  Jia Liu,et al.  The Expression of PD-1 Ligands and Their Involvement in Regulation of T Cell Functions in Acute and Chronic Woodchuck Hepatitis Virus Infection , 2011, PloS one.

[99]  E John Wherry,et al.  T cell exhaustion , 2011 .

[100]  R. Bhadra,et al.  Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1–PDL-1 blockade , 2011, Proceedings of the National Academy of Sciences.

[101]  L. Kaer,et al.  T Cells from Programmed Death-1 Deficient Mice Respond Poorly to Mycobacterium tuberculosis Infection , 2011, PloS one.

[102]  M. Maini,et al.  Role of the coinhibitory receptor cytotoxic T lymphocyte antigen‐4 on apoptosis‐Prone CD8 T cells in persistent hepatitis B virus infection , 2011, Hepatology.

[103]  D. Munn,et al.  Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. , 2011, Blood.

[104]  A. Sher,et al.  CD4 T Cells Promote Rather than Control Tuberculosis in the Absence of PD-1–Mediated Inhibition , 2011, The Journal of Immunology.

[105]  J. Haas,et al.  The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus‐specific CD8+ T‐cell function , 2010, Hepatology.

[106]  J. Wolchok,et al.  Anti-GITR antibodies--potential clinical applications for tumor immunotherapy. , 2010, Current opinion in investigational drugs.

[107]  Jenna M. Sullivan,et al.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.

[108]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[109]  S. Almo,et al.  Programmed death-1 (PD-1)–deficient mice are extraordinarily sensitive to tuberculosis , 2010, Proceedings of the National Academy of Sciences.

[110]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  J. Allison,et al.  Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals , 2010, Clinical Cancer Research.

[112]  M. Massari,et al.  Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. , 2010, Gastroenterology.

[113]  Loise M. Francisco,et al.  PD-L1 regulates the development, maintenance, and function of induced regulatory T cells , 2009, The Journal of experimental medicine.

[114]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[115]  B. Walker,et al.  PD-1 and CTLA-4 Inhibitory Cosignaling Pathways in HIV Infection and the Potential for Therapeutic Intervention , 2009, The Journal of Immunology.

[116]  V. Perovic,et al.  B7-H1 Blockade Increases Survival of Dysfunctional CD8+ T Cells and Confers Protection against Leishmania donovani Infections , 2009, PLoS pathogens.

[117]  S. Pierce,et al.  World Malaria Day 2009: What Malaria Knows about the Immune System That Immunologists Still Do Not , 2009, The Journal of Immunology.

[118]  G. Freeman,et al.  The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T‐cell activation , 2009, Immunological reviews.

[119]  G. Freeman,et al.  Enhancing SIV-Specific Immunity In Vivo by PD-1 Blockade , 2008, Nature.

[120]  E. Wherry,et al.  Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. , 2008, Gastroenterology.

[121]  G. Freeman,et al.  Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. , 2008, Gastroenterology.

[122]  D. Fuchs,et al.  Immune Activation Driven by CTLA-4 Blockade Augments Viral Replication at Mucosal Sites in Simian Immunodeficiency Virus Infection1 , 2008, The Journal of Immunology.

[123]  J. Lukens,et al.  Blockade of PD-1/B7-H1 Interaction Restores Effector CD8+ T Cell Responses in a Hepatitis C Virus Core Murine Model1 , 2008, The Journal of Immunology.

[124]  G. Pedrazzi,et al.  Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. , 2008, Journal of hepatology.

[125]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[126]  S. Lewin,et al.  The phenotype of hepatitis B virus–specific T cells differ in the liver and blood in chronic hepatitis B virus infection , 2007, Hepatology.

[127]  E. Wherry,et al.  Molecular signature of CD8+ T cell exhaustion during chronic viral infection. , 2007, Immunity.

[128]  G. Freeman,et al.  PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status , 2007, AIDS.

[129]  E. Rosenberg,et al.  Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction , 2007, Nature Immunology.

[130]  K. Murphy,et al.  Ligation of B and T Lymphocyte Attenuator Prevents the Genesis of Experimental Cerebral Malaria1 , 2007, The Journal of Immunology.

[131]  B. Palmer,et al.  Upregulation of PD-1 Expression on Circulating and Intrahepatic Hepatitis C Virus-Specific CD8+ T Cells Associated with Reversible Immune Dysfunction , 2007, Journal of Virology.

[132]  G. Gao,et al.  PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. , 2007, Blood.

[133]  G. Freeman,et al.  PD-1:PD-L1 Interactions Contribute to the Functional Suppression of Virus-Specific CD8+ T Lymphocytes in the Liver1 , 2007, The Journal of Immunology.

[134]  A. Bertoletti,et al.  Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection , 2007, Journal of Virology.

[135]  D. Fuchs,et al.  CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. , 2006, Blood.

[136]  G. Freeman,et al.  Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade , 2006, The Journal of experimental medicine.

[137]  R. Koup,et al.  PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection , 2006, The Journal of experimental medicine.

[138]  Philip J. R. Goulder,et al.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.

[139]  R. Balderas,et al.  Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction , 2006, Nature Medicine.

[140]  Yongliang Zhang,et al.  Regulation of T cell activation and tolerance by PDL2. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[141]  G. Freeman,et al.  Tissue expression of PD-L1 mediates peripheral T cell tolerance , 2006, The Journal of experimental medicine.

[142]  G. Freeman,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[143]  H. Waldmann,et al.  Resistance of regulatory T cells to glucocorticoid‐viduced TNFR family‐related protein (GITR) during Plasmodium yoelii infection , 2005 .

[144]  V. Kuchroo,et al.  The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity , 2005, Nature Immunology.

[145]  M. Good,et al.  Plasmodium yoelii Can Ablate Vaccine-Induced Long-Term Protection in Mice1 , 2005, The Journal of Immunology.

[146]  F. Chisari,et al.  Oscillating CD8(+) T cell effector functions after antigen recognition in the liver. , 2005, Immunity.

[147]  Lieping Chen,et al.  In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses , 2005, The Journal of experimental medicine.

[148]  Wenjun Ouyang,et al.  A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[149]  C. Drake,et al.  Role of LAG-3 in regulatory T cells. , 2004, Immunity.

[150]  C. June,et al.  SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 , 2004, The Journal of Immunology.

[151]  G. Freeman,et al.  Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses , 2003, European journal of immunology.

[152]  Lieping Chen,et al.  Cooperative B7-1/2 (CD80/CD86) and B7-DC Costimulation of CD4+ T Cells Independent of the PD-1 Receptor , 2003, The Journal of experimental medicine.

[153]  G. Freeman,et al.  Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1 , 2003, The Journal of Immunology.

[154]  D. Pardoll,et al.  Expression of Programmed Death 1 Ligands by Murine T Cells and APC1 , 2002, The Journal of Immunology.

[155]  J. Shimizu,et al.  Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance , 2002, Nature Immunology.

[156]  D. Pardoll,et al.  B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells , 2001, The Journal of experimental medicine.

[157]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[158]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[159]  D. Vergani,et al.  The Role of Virus-Specific Cd8+ Cells in Liver Damage and Viral Control during Persistent Hepatitis B Virus Infection , 2000, The Journal of experimental medicine.

[160]  M. Wahlgren,et al.  Age-Related Buildup of Humoral Immunity against Epitopes for Rosette Formation and Agglutination in African Areas of Malaria Endemicity , 1998, Infection and Immunity.

[161]  Kevin Marsh,et al.  Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria , 1998, Nature Medicine.

[162]  J. Langhorne,et al.  Gene-targeted mice lacking B cells are unable to eliminate a blood stage malaria infection. , 1996, Journal of immunology.

[163]  J. Allison,et al.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.

[164]  J. Allison,et al.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones , 1992, Nature.

[165]  J. Podoba,et al.  CD4+ and CD8+ T lymphocytes both contribute to acquired immunity to blood-stage Plasmodium chabaudi AS , 1991, Infection and immunity.

[166]  L. Rénia,et al.  Hepatic phase of malaria is the target of cellular mechanisms induced by the previous and the subsequent stages. A crucial role for liver nonparenchymal cells. , 1990, Immunology letters.

[167]  J. Langhorne,et al.  The role of CD4+ T cells in the protective immune response to Plasmodium chabaudi in vivo. , 1990, Immunology letters.

[168]  I. McGregor,et al.  Gamma-Globulin and Acquired Immunity to Human Malaria , 1961, Nature.

[169]  Lei Li,et al.  Hepatic expansion of virus-specific CD8+BTLA+ T cells with regulatory properties in chronic hepatitis B virus infection. , 2017, Cellular immunology.

[170]  S. Lewin,et al.  Cancer therapies in HIV cure research , 2017, Current opinion in HIV and AIDS.

[171]  S. Lewin,et al.  HIV persistence and T-cell activation in blood, rectal and lymph node tissue in HIV-infected individuals receiving suppressive ART. , 2017, The Journal of infectious diseases.

[172]  Anh-Hoa Nguyen,et al.  A phase1 study evaluating anti-PD-1 treatment with or without GS-4774 in HBeAg negative chronic hepatitis B patients , 2017 .

[173]  A. Korman,et al.  FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. , 2015, Cancer cell.

[174]  H. Clark,et al.  The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells , 2009, Nature Immunology.

[175]  H. Waldmann,et al.  Resistance of regulatory T cells to glucocorticoid-induced [corrected] TNFR family-related protein (GITR) during Plasmodium yoelii infection. , 2005, European journal of immunology.

[176]  C. Ware,et al.  B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator , 2005, Nature Immunology.

[177]  Alan D. Lopez,et al.  The Global Burden of Disease Study , 2003 .

[178]  P. Druilhe,et al.  Premunition against Plasmodium falciparum in a malaria hyperendemic village in Myanmar. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[179]  Rafi,et al.  Prolonged Exposure to HIV Reinforces a Poised Epigenetic Program for PD-1 Expression in Virus-Specific CD8 T Cells , 2022 .